1,25-Dihydroxyvitamin D3 Induces Phospholipase D-1 Expression in Primary Mouse Epidermal Keratinocytes*

Richard D. Griner, Feng Qin, EunMi Jung, Christopher K. Sue-Ling, Kimberly B. Crawford, RaShawn Mann-Blakeney, Roni J. Bollag, and Wendy Bollinger BollagDagger

From the Departments of Medicine (Dermatology) and Cellular Biology and Anatomy, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, Georgia 30912

    ABSTRACT
Top
Abstract
Introduction
References

The hormone 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) elicits the programmed pattern of differentiation in epidermal keratinocytes. Based on data indicating a potential role of phospholipase D (PLD) in mediating keratinocyte differentiation, we investigated the effect of 1,25(OH)2D3 on PLD expression. A 24-h exposure to 1,25(OH)2D3 stimulated PLD-1, but not PLD-2, mRNA expression. This 1,25(OH)2D3-enhanced expression was accompanied by increased total PLD and PLD-1 activity. Time course studies indicated that 1,25(OH)2D3 induced PLD-1 expression by 8 h, with a maximal increase at 20-24 h. Exposure to 1,25(OH)2D3 inhibited proliferation over the same time period with similar kinetics. Expression of the early (spinous) differentiation marker keratin 1 decreased in response to 1,25(OH)2D3 over 12-24 h. Treatment with 1,25(OH)2D3 enhanced the activity of transglutaminase, a late (granular) differentiation marker, by 12 h with a maximal increase after 24 h. In situ hybridization studies demonstrated that the highest levels of PLD-1 expression are in the more differentiated (spinous and granular) layers of the epidermis, with little expression in basal keratinocytes. Our results suggest a role for PLD expression/activity during keratinocyte differentiation.

    INTRODUCTION
Top
Abstract
Introduction
References

The skin is a dynamic organ consisting of the dermis and epidermis, with the latter continuously undergoing regeneration to replace cells lost through normal exposure to the environment. The epidermis is composed of several cell layers. The deepest layer, located at the dermal-epidermal junction, is the basal layer, consisting of the undifferentiated basal keratinocytes, which continuously proliferate. As the cells migrate up through the epidermis, keratinocytes undergo a distinct pattern of differentiation that is essential for the function of the skin as a protective barrier. This pattern is characterized by growth arrest and expression of the mature cytokeratins 1 and 10 in the first differentiated layer of the epidermis, the spinous layer. Early differentiation in the spinous layer is followed by late differentiation in the granular layer accompanied by expression of proteins, including the enzyme transglutaminase, that are essential for the formation of the cornified envelope and corneocytes. The corneocytes are terminally differentiated and constitute the outer layer of the epidermis, the cornified layer, which gives skin its resistance to mechanical stresses (for reviews, see Refs. 1 and 2).

Despite the importance of the keratinocyte differentiation program and intense investigation, both the extracellular and the intracellular signals controlling this process are largely unknown. Numerous studies have pointed to a role for 1alpha ,25-dihydroxyvitamin D3 (1,25(OH)2D3)1 in regulating keratinocyte differentiation (reviewed in Ref. 1). In fact, this compound and its structural analogs have been used successfully to treat psoriasis (reviewed in Ref. 3), a human disease characterized by hyperproliferation, abnormal differentiation, and inflammation of the skin. A physiologic role for 1,25(OH)2D3 in regulating keratinocyte differentiation in the epidermis in vivo is suggested by several lines of evidence: 1) keratinocytes express the 1alpha -hydroxylase, which converts the inactive 25-hydroxyvitamin D3 to its active 1,25-dihydroxymetabolite (reviewed in Ref. 1); 2) receptors for 1,25(OH)2D3 are present in the skin and in epidermal keratinocytes (references cited in Ref. 4); and 3) 1,25(OH)2D3 triggers two major events in keratinocytes in vitro: inhibition of proliferation and induction of differentiation (reviewed in Ref. 1).

The mechanism by which 1,25(OH)2D3 inhibits proliferation and stimulates differentiation is still unclear. This hormone is thought to function through the vitamin D receptor, a transcription factor affecting expression of genes possessing vitamin D response elements. However, the keratin 1 gene is the only keratinocyte differentiation marker known to possess a 1,25(OH)2D3 response element (5, 6), and the expression of this marker is inhibited by 1,25(OH)2D3 (7). In addition, 1,25(OH)2D3 was recently shown to enhance the expression of several phosphoinositide-specific phospholipase C isoenzymes (8), the activity of which generates diacylglycerol (DAG). DAG, in turn, is known to regulate the activity of protein kinase C (PKC), and numerous data suggest the involvement of PKC in the regulation of keratinocyte growth and differentiation (reviewed in Refs. 1 and 9).

Although PKC-activating DAG can be generated directly by phosphoinositide turnover via phospholipase C, such DAG can also be generated indirectly by an additional pathway. Diacylglycerol is generated by the combination of phospholipase D (PLD), which hydrolyzes phospholipids to generate phosphatidic acid (PA), and PA phosphohydrolase, which dephosphorylates PA to yield DAG (reviewed in Ref. 10). Indeed, in several cell systems, PLD activity has been shown to underlie at least a portion of agonist-induced sustained DAG production (reviewed in Ref. 10), and it has been proposed that chronic elevations in DAG content are the product of the combined activities of PLD and PA phosphohydrolase (11).

Several lines of evidence support a role for PLD in differentiation of keratinocytes. For example, the tetrasialo ganglioside GQ1b induces PLD activation, a sustained elevation in DAG content, and induction of keratinocyte differentiation (12, 13). Studies in our laboratory also provide evidence for an involvement of PLD in keratinocyte growth inhibition and differentiation. Specifically, incubation of epidermal keratinocytes with bacterial PLD results in inhibition of proliferation and an increase in the activity of a marker of differentiation, transglutaminase (14). In addition, staurosporine and 12-O-tetradecanoylphorbol-13-acetate elicit sustained PLD activation and also induce transglutaminase activity in primary mouse keratinocytes.2 Finally, previous findings with two microbial toxins, epidermal cell differentiation inhibitor derived from Staphylococcus aureus E-1 and exoenzyme C3 from Clostridium botulinum, also support an involvement of PLD in keratinocyte differentiation. These toxins inhibit the differentiation of human epidermal keratinocytes through a common mechanism (15) involving ADP-ribosylation of small GTP-binding proteins of the Rho family. Since RhoA regulates PLD (reviewed in Ref. 16) and since in other systems C3 exoenzyme is known to block PLD activation (17), it is possible that the ability of epidermal cell differentiation inhibitor and C3 to inhibit keratinocyte differentiation may be through their inhibition of the activity of PLD.

Two isoforms of PLD, PLD-1 and PLD-2, have recently been cloned, sequenced, and characterized (18-21). Both isoenzymes utilize phosphatidylcholine as a substrate and require phosphatidylinositol 4,5-bisphosphate as a cofactor (19, 22). Interestingly, two recent reports have observed changes in the expression and/or activity of PLD-1 associated with differentiation of C6 glioma (23) and HL-60 cells (24). Furthermore, PLD-1 appears to represent the isoform sensitive to microbial toxin inhibition, since this isoenzyme is regulated by small GTP-binding proteins, such as Rho. On the other hand, PLD-2 exhibits constitutive activity (22), and its function is unknown (19, 22).

Because 1,25(OH)2D3 increases the expression of phosphoinositide-specific phospholipase, which generates PKC-activating DAG, and because PLD not only generates DAG but also may be an important signaling enzyme during keratinocyte differentiation, we hypothesized that 1,25(OH)2D3 may also exert its effects on keratinocyte differentiation by modulating PLD expression and/or activity. Therefore, we investigated the effects of 1,25(OH)2D3 on PLD-1 and -2 expression and PLD activity. We report that 1,25(OH)2D3 induces PLD-1, but not PLD-2, expression. The current work establishes the time course of the induction of PLD-1 expression in primary mouse epidermal keratinocytes in response to 1,25(OH)2D3 and demonstrates a concomitant enhancement of PLD activity. Furthermore, the data correlate the activation of this signaling pathway with the induction and progression of keratinocyte differentiation.

    EXPERIMENTAL PROCEDURES

Materials-- Calcium-free minimal essential medium and antibiotics were obtained from Biologos, Inc. (Maperville, IL). Bovine pituitary extract, epidermal growth factor, and TriZOL reagent were purchased from Life Technologies, Inc. ITS+ (6.25 µg/ml insulin, 6.25 µg/ml transferrin, 6.25 ng/ml selenous acid, 5.35 µg/ml linoleic acid, and 0.125% bovine serum albumin) was supplied by Collaborative Biomedical Products (Bedford, MA). All radiolabeled chemicals were purchased from NEN Life Science Products. Silica Gel 60 TLC plates with concentrating zone were obtained from EM Science (Gibbstown, NJ). Phosphatidic acid and phosphatidylethanol standards, as well as phosphatidylcholine and phosphatidylethanolamine, were obtained from Avanti Polar Lipids (Alabaster, AL). Phosphatidylinositol 4,5-bisphosphate was purchased from Calbiochem. GF/A filters were purchased from Whatman International, Ltd. (Maidstone, United Kingdom), and support filters were obtained from Millipore Corp. (Bedford, MA). In situ hybridizations were performed using a DIG/Genius RNA labeling kit from Boehringer Mannheim. All other reagents were purchased from Sigma.

Cell Isolation and Culture-- Epidermal keratinocytes harvested from neonatal ICR mice according to the method of Yuspa and Harris (25) were used to initiate primary cultures. Cells were plated at a density of 25,000 cells/cm2 and were allowed to attach overnight in the presence of keratinocyte plating medium composed of calcium-free minimal essential medium supplemented with 2% dialyzed fetal bovine serum, 50 µM calcium chloride, 5 ng/ml epidermal growth factor, 2 mM glutamine, ITS+, 100 units/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml fungizone. Following attachment, the cells were refed with keratinocyte growth medium composed of the above medium in which serum was deleted and 90 µg/ml bovine pituitary extract was added.

RNA Isolation and Northern Blot Analysis-- Near confluent cultures of primary keratinocytes were refed with keratinocyte growth medium supplemented with 250 nM 1,25(OH)2D3 or vehicle control. After the indicated time periods, the cells were lysed with 1.0 ml of TriZOL reagent, and total RNA was isolated according to the manufacturer's instructions. Total RNA (15 µg) was separated on 1.2% formaldehyde-agarose gels and transferred to GeneScreen (NEN Life Science Products) membrane. Following prehybridization overnight, the blots were probed overnight in Church-Gilbert buffer (0.5 M sodium phosphate, 7% SDS, 1% bovine serum albumin, pH 7.6) at 65 °C with a random hexamer-primed [32P]dCTP-labeled probe fragment. Blots were then washed four times for 5 min each at room temperature in 2× SSC plus 0.1% SDS and two times for 30 min each at 65 °C in 0.1× SSC plus 0.1% SDS (1× SSC: 150 mM NaCl, 15 mM sodium citrate, pH 7.0) and exposed to film for 6-10 days. Quantitation was performed using a Bio-Rad model GS-700 imaging densitometer, and the density of each band was normalized to the density of the corresponding glyceraldehyde-3-phosphate dehydrogenase band. Probe fragments consisted of nucleotides 542-1390 of murine PLD-1 (20) and 397-1229 of murine PLD-2 (22). The probe for cytokeratin K1 was kindly provided by Dr. Stuart Yuspa (NCI, National Institutes of Health, Bethesda, MD).

Measurement of Total Phospholipase D Activity in Intact Cells-- Total PLD activity was assayed as detailed in Ref. 26 and is described briefly. To determine an acute effect of 1,25(OH)2D3 on PLD activity, near confluent cultures of primary keratinocytes (densities of 15,000-30,000 cells/cm2) were labeled for 20-24 h with [3H]oleic acid and then refed with keratinocyte growth medium supplemented with 250 nM 1,25(OH)2D3 or vehicle control in the presence of 0.5% ethanol for an additional 30 min. To determine a chronic effect of 1,25(OH)2D3 on PLD activity, keratinocytes were incubated for 24 h with 250 nM 1,25(OH)2D3 or vehicle control prior to the addition of approximately 5 µCi/sample of [14C]ethanol in ethanol (final concentration = 0.5%) for an additional 1 h. The incubations were terminated by aspirating the medium and lysing the cells by the addition of 0.2% SDS containing 5 mM EDTA. The radiolabeled phosphatidylethanol was then extracted into chloroform/methanol (2:1, v/v), separated by thin layer chromatography, visualized with autofluorography using En3Hance, and quantified by liquid scintillation spectrometry.

Measurement of Phospholipase D-1 Activity in Vitro-- Rho- and ADP-ribosylation factor (ARF)-stimulatable PLD-1 activity was assayed in vitro essentially as in Ref. 27. Near confluent epidermal keratinocytes were treated for 24 h with control vehicle (0.05% ethanol) or 250 nM 1,25(OH)2D3. Cells were rinsed once with phosphate-buffered saline and scraped from the plate in 300 µl of buffer A (25 mM HEPES, pH 7.4, 100 mM KCl, 3 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 5 mM dithiothreitol, and protease inhibitors (0.5 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride, 2.1 µM leupeptin, 1.8 µg/ml aprotinin, 1 µg/ml pepstatin A with or without 2.5 µg/ml trypsin inhibitor and 1 µg/ml chymostatin)). Keratinocytes were then homogenized using a pellet pestle (Kontes, Vineland, NJ) and centrifuged to remove unlysed cells. The resulting supernatant (40 µl) was assayed in vitro for PLD activity in the presence and absence of 1 µM each of GTPgamma S-loaded Rho and ARF in a final volume of 150 µl of 50 mM HEPES, pH 7.4, 3 mM EGTA, 80 mM KCl, 1 mM dithiothreitol, 3 mM MgCl2, and 2 mM CaCl2. The substrate consisted of phospholipid vesicles composed of 320 µg of phosphatidylethanolamine, 20 µg of phosphatidylcholine, 14 µg of phosphatidylinositol 4,5-bisphosphate, and 50 µCi of [choline-methyl-3H]dipalmitoylphosphatidylcholine and prepared by sonication in 2.5 ml of 20 mM HEPES, pH 7.4. Reactions were initiated by the addition of the phospholipid vesicle mixture (1.3 µCi/sample) and proceeded for 30 min at 37 °C with shaking. Reactions were terminated, and unreacted [3H]phosphatidylcholine was precipitated by the addition of ice-cold 20% trichloroacetic acid and bovine serum albumin. Samples were centrifuged at 4 °C, and [3H]choline released into the supernatant was quantified by liquid scintillation spectrometry. Blanks to which no cell lysate was added were performed, and the determined radioactivity was subtracted from all samples. Values were then expressed as the difference between PLD activity assayed in the presence of Rho and ARF versus in the absence of these two small GTP-binding proteins. Controls in which human PLD-1- or mouse PLD-2-overexpressing (baculovirus-infected) Sf9 membranes were assayed as above showed that PLD-1 activity was stimulated in the presence of Rho and ARF, whereas PLD-2 activity was unaffected (and/or slightly inhibited), as previously reported (22). Purified recombinant, baculovirus-expressed human Rho and ARF and PLD-overexpressing insect cell membranes were generous gifts of Dr. Nancy Pryer (Onyx Pharmaceuticals, Richmond, CA).

Measurement of DNA Synthesis-- Near confluent cultures of primary keratinocytes were refed with keratinocyte growth medium supplemented with the indicated concentrations of 1,25(OH)2D3 or vehicle control. After the indicated time periods, the cells were labeled with 1 µCi/ml [3H]thymidine for approximately 1 h. Cells were washed twice with phosphate-buffered saline, and reactions were terminated using ice-cold 5% trichloroacetic acid. Cells were washed sequentially with 5% trichloroacetic acid followed by deionized water and were solubilized in 0.3 M NaOH. An aliquot of this NaOH extract was counted in a liquid scintillation spectrometer.

Measurement of Cellular Transglutaminase Activity-- Near confluent cultures of primary keratinocytes were refed with keratinocyte growth medium supplemented with 250 nM 1,25(OH)2D3 or vehicle control. Cells were harvested, and transglutaminase activity was measured according to the method of Folk and Chung (28) with minor modifications. Specifically, dimethylcasein was substituted for alpha -casein, and reactions were permitted to continue overnight before isolating the [3H]putrescine dimethylcasein product on filters with ice-cold trichloroacetic acid. The radiolabeled product was then counted in a liquid scintillation spectrometer and normalized to protein content of the samples as determined using the micro-BCA protein assay with bovine serum albumin as the standard.

In Situ Hybridization-- The expression of PLD-1 mRNA in neonatal mouse skin was detected by in situ hybridization as described by Wilkinson (29), with modifications for use with tissue sections. Briefly, neonatal mouse skins were dissected and fixed in 4% paraformaldehyde overnight at 4 °C. Fixed skins were then dehydrated in ethanol and xylene and embedded in paraffin. Seven-µm-thick sections were cut, deparaffinated, and rehydrated. The sections were treated with proteinase K and post-fixed in 4% paraformaldehyde, 0.2% glutaraldehyde prior to hybridization with a digoxigenin-labeled PLD-1 probe (nucleotides 542-1390, as above) at 70 °C overnight in a solution containing 50% formamide, 5× SSC, 1% SDS, 5 mg/ml heparin, and 50 mg/ml yeast tRNA. Following hybridization, the tissue sections were washed sequentially in 2× SSC plus 1% SDS, 1× SSC plus 1% SDS, and 0.5× SSC plus 1% SDS for 1 h each at 70 °C. The sections were then incubated with alkaline phosphatase-conjugated anti-digoxigenin antibody for 2 h and washed in TBST overnight. The colorimetric reaction for alkaline phosphatase was performed using nitro blue tetrazolium and X-phosphate.

Statistics-- The data are presented as means ± S.E. Each keratinocyte preparation represents a separate experiment (n = 1). Data were analyzed using analysis of variance or Student's t test, as appropriate, to determine if individual time points or treatments differed significantly from control. The level of significance was p < 0.05.

    RESULTS

Induction of Phospholipase D-1 Expression and Activity by 1,25(OH)2D3-- To determine the ability of 1,25(OH)2D3 to modulate the expression of PLD, Northern blot analysis was performed. Near confluent cultures of primary mouse keratinocytes were treated with 250 nM 1,25(OH)2D3 (a maximal growth-inhibitory concentration, as shown in Fig. 4A) or vehicle for 24 h, and total RNA was isolated. RNA was analyzed by Northern hybridization with probes for PLD-1 and PLD-2 as described under "Experimental Procedures." PLD-1 mRNA levels were specifically increased by 250 nM 1,25(OH)2D3, while PLD-2 levels were unchanged (Fig. 1). Subsequently, treatment of near confluent cultures of primary mouse keratinocytes with 250 nM 1,25(OH)2D3 for various times revealed that PLD-1 expression increased to 167% of control within 8 h and reached a peak increase of 289% of control at 24 h (Fig. 2).


View larger version (62K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of 1,25(OH)2D3 on the expression of PLD-1 and -2 in primary cultures of mouse keratinocytes. Near confluent cultures of primary mouse keratinocytes were treated with 250 nM 1,25(OH)2D3 (D3) or vehicle control (C) for 24 h, and Northern blot analysis was performed. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) bands are shown to indicate approximately equal loading of 15 µg of total RNA. Also shown are molecular size markers to indicate the approximate size of each transcript.


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 2.   The time-dependent effect of 1,25(OH)2D3 on the expression of PLD-1 in primary cultures of mouse keratinocytes. Near confluent cultures of primary mouse keratinocytes were treated with 250 nM 1,25(OH)2D3 (D3) or vehicle control (C) for the indicated time periods, and Northern blot analysis was performed. Two bands are typically recognized by the PLD-1 probe; the size differential of these two bands (the upper band is 7.5 kilobase pairs, and the lower band is 5 kilobase pairs) suggests that they cannot represent the two splice variants of PLD-1 described previously, PLD1a and PLD1b, which differ by only 114 base pairs (20). Although the precise identities of the two bands are unclear, the lower band was used for quantitation, since the 5-kilobase pair size matches that defined as the cDNA coding region (20). The density of the PLD-1 band was normalized to the density of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) band within each lane, and the level of PLD-1 expression by treated keratinocytes is expressed as a percentage of the control PLD-1 expression for each time point. The compiled results of multiple experiments are expressed graphically, and one representative blot containing a range of time points is shown. Asterisks indicate that PLD-1 expression by treated keratinocytes is significantly greater than the control PLD-1 expression at the given time point (means ± S.E., n = 3-5, p < 0.05).

To establish that the increase in PLD-1 mRNA levels resulted in increased enzyme activity, total PLD activity was measured in near confluent cultures of primary mouse keratinocytes following both acute (30-min) and chronic (24-h) exposures to 250 nM 1,25(OH)2D3. After 30 min, there was no significant effect of 1,25(OH)2D3 on PLD activity (Fig. 3A). However, after 24 h the PLD activity was increased to 140% of control (Fig. 3A). Thus, 1,25(OH)2D3 increased both PLD-1 expression and PLD activity within 24 h in primary cultures of mouse keratinocytes.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3.   The acute and chronic effects of 1,25(OH)2D3 on total PLD and PLD-1 activity in primary cultures of mouse keratinocytes. A, near confluent cultures of primary mouse keratinocytes were treated with 250 nM 1,25(OH)2D3 or vehicle control (Con) for the indicated time periods, and PLD activity was assayed by measuring the production of phosphatidylethanol (PEt). Values are expressed as percentages of control and represent the means ± S.E. of three separate experiments performed in duplicate. *, p < 0.05. B, near confluent cultures of primary mouse keratinocytes were treated with 250 nM 1,25(OH)2D3 or vehicle control for 24 h, and cell homogenates were prepared. Rho- and ARF-stimulatable PLD-1 activity in the homogenate was then measured in vitro, and PLD-1 activity was calculated as described under "Experimental Procedures." Values are expressed as a percentage of control and represent the means ± S.E. of three experiments performed in triplicate.

Previous reports indicate that PLD-1 activity is enhanced by the small GTP-binding proteins, Rho and ARF (reviewed in Ref. 16). To verify that the observed increase in PLD activity represented PLD-1, we measured Rho- and ARF-stimulatable PLD activity in vitro in homogenates of cells preexposed for 24 h to control vehicle or 250 nM 1,25(OH)2D3. We observed an approximate 3-fold increase in Rho- and ARF-stimulated activity in 1,25(OH)2D3-pretreated cell homogenates (Fig. 3B), consistent with our observations of an approximate 3-fold increase in PLD-1 expression, as well as enhanced total PLD activity, in response to 1,25(OH)2D3.

Induction of Keratinocyte Growth Arrest by 1,25(OH)2D3-- To confirm that 1,25(OH)2D3 induces growth arrest of primary cultures of mouse keratinocytes, we examined the ability of 1,25(OH)2D3 to inhibit proliferation by examining the incorporation of [3H]thymidine into DNA. 1,25(OH)2D3 inhibited proliferation of primary mouse keratinocytes in both a concentration- and time-dependent manner (Fig. 4, A and B). Following a 24-h exposure, only 0.1 nM 1,25(OH)2D3 was required to significantly inhibit [3H]thymidine incorporation, and the inhibition was maximal between 100 and 250 nM (Fig. 4A). Thus, 250 nM 1,25(OH)2D3 was established as the concentration to be used in all subsequent experiments. At this concentration, [3H]thymidine incorporation was significantly decreased after only 8 h (75% of control), and maximal inhibition of [3H]thymidine incorporation was achieved by 24 h (18% of control) (Fig. 4B).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 4.   The concentration- (A) and time-dependent (B) effects of 1,25(OH)2D3 on [3H]thymidine incorporation in primary cultures of mouse keratinocytes. Near confluent cultures of primary mouse keratinocytes were treated with the indicated concentrations of 1,25(OH)2D3 or vehicle control for 24 h (A) or with 250 nM 1,25(OH)2D3 for the indicated time periods (B), and radiolabel was added for an additional 1 h. The data are expressed as a percentage of the [3H]thymidine incorporation by treated keratinocytes compared with the corresponding control at the same time point. The asterisks indicate that [3H]thymidine incorporation by treated keratinocytes is significantly less than the control [3H]thymidine incorporation at the given time point (means ± S.E., n = 3-7, p < 0.05).

Induction of Keratinocyte Differentiation by 1,25(OH)2 D3-- Expression of cytokeratin K1, a marker of the early (spinous) stage of keratinocyte differentiation, was measured by Northern blot analysis in order to determine the ability of 1,25(OH)2D3 to induce cultured basal keratinocytes to differentiate to spinous keratinocytes. Near confluent cultures of primary mouse keratinocytes were treated with 250 nM 1,25(OH)2D3 or vehicle for the indicated time periods, and total RNA was isolated. Cytokeratin K1 mRNA levels began to decrease after 8 h, and K1 mRNA levels were significantly decreased by 12 h to 41% of control (Fig. 5). Thus, 250 nM 1,25(OH)2D3 decreased the expression of a spinous stage marker in primary mouse keratinocytes.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5.   The time-dependent effect of 1,25(OH)2D3 on the expression of K1 in primary cultures of mouse keratinocytes. Near confluent cultures of primary mouse keratinocytes were treated with 250 nM 1,25(OH)2D3 (D3) or vehicle control (C) for the indicated time periods, and Northern blot analysis was performed. The density of the K1 band was normalized to the density of the corresponding glyceraldehyde-3-phosphate dehydrogenase band in each lane, and the level of K1 expression by treated keratinocytes is expressed as a percentage of the control K1 expression for each time point. The compiled results of multiple experiments are expressed graphically, and one representative blot containing a range of time points is shown. The asterisks indicate that K1 expression by treated keratinocytes is significantly less than the control K1 expression at the given time point (means ± S.E., n = 3-5, p < 0.05).

Activity of transglutaminase, a late (granular) stage marker of keratinocyte differentiation, was measured using a radiolabeled substrate in order to determine the ability of 1,25(OH)2D3 to induce cultured keratinocytes to differentiate to the granular stage. Near confluent cultures of primary mouse keratinocytes were treated with 250 nM 1,25(OH)2D3 or vehicle for the indicated time periods, and transglutaminase activity was measured as described under "Experimental Procedures." Transglutaminase activity was increased to 160% of control by 1,25(OH)2D3 after 12 h, and after 24 h transglutaminase activity was maximally increased to 214% of control (Fig. 6). Thus, 1,25(OH)2D3 increased the activity of a late stage marker of differentiation in primary cultures of mouse keratinocytes. Furthermore, the increase in transglutaminase activity closely followed the increase in expression of PLD-1.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6.   The time-dependent effect of 1,25(OH)2D3 on the activity of transglutaminase in primary cultures of mouse keratinocytes. Near confluent cultures of primary mouse keratinocytes were treated with 250 nM 1,25(OH)2D3 or vehicle control for the indicated time periods, and transglutaminase activity was assayed. For each experiment, the transglutaminase activity in treated keratinocytes was normalized to the control transglutaminase activity of the same time point, and the data are expressed as the means of the percentage of control (means ± S.E., n = 4-7, p < 0.05).

Expression of PLD-1 by Neonatal Mouse Epidermis-- To establish that PLD-1 expression is important for the the intermediate stages of mouse keratinocyte differentiation in vivo, in situ hybridization using sense and antisense probes for PLD-1 was performed on neonatal mouse skins as described under "Experimental Procedures." The cells between the basal and cornified layers are in the spinous and granular stages of differentiation, and this region showed strong staining for PLD-1 (Fig. 7, A and C). The undifferentiated basal cells and the terminally differentiated and metabolically inactive cornified cells exhibited relatively light staining. Hybridization with the control probe showed light and diffuse staining throughout the layers (Fig. 7, B and D). Thus, the importance of PLD-1 expression during the intermediate stages of differentiation of cultured keratinocytes is supported by the expression of PLD-1 in the actively differentiating cells of neonatal mouse epidermis.


View larger version (147K):
[in this window]
[in a new window]
 
Fig. 7.   In situ hybridization of neonatal mouse epidermis using sense and antisense probes for phospholipase D-1. Freshly dissected neonatal mouse skins were fixed and hybridized with an antisense probe recognizing the mRNA for PLD-1 (A and C) or a sense (control) probe capable of recognizing the complementary strand (B and D). Magnifications are as follows: × 20 (A and B) and × 40 (C and D). B, basal layer; S/G, spinous and granular layers; C, cornified layer. Shown is the result of one experiment representative of two.


    DISCUSSION

The ability of 1,25(OH)2D3 to increase the expression of phosphoinositide-specific phospholipase C isoforms (8) led us to examine the effect of this sterol hormone on another DAG-generating signaling enzyme, PLD. We found that 1,25(OH)2D3 specifically increased the expression of the PLD-1 isoform of PLD without affecting PLD-2 expression (Fig. 1). The specificity of this stimulation suggests that the observed increase in expression is not due to a global enhancement of transcription and/or message stability.

The time course of PLD-1 expression (Fig. 2) is consistent with several previous studies that have documented the effect of 1,25(OH)2D3 on the expression of inducible genes. While the mRNA levels of some 1,25(OH)2D3-responsive genes increase within 1-2 h (e.g. tumor necrosis factor-alpha (30)), other genes require longer time periods for their induction. For example, the expression of transforming growth factor-beta is increased after a 6-h exposure of human keratinocytes to 1,25(OH)2D3 (31). Similarly, two genes that respond to 1,25(OH)2D3 at later time points are known to contain vitamin D response elements in their respective promoters (32). Specifically, in mouse epidermal cells osteopontin expression is increased within 4 h by 1,25(OH)2D3 (33), and in vivo, 25-hydroxyvitamin D3 24-hydroxylase is induced between 3 and 6 h in intestine and kidney (32).

The 1,25(OH)2D3-stimulated PLD-1 expression translates into an increase in PLD activity as well. The hormone has no acute effect on PLD activity (unlike hormones that stimulate cells through tyrosine kinase or G-protein-coupled receptors) but does activate PLD over 24 h (Fig. 3A), consistent with the time course of enhanced PLD-1 expression. On the other hand, the pronounced change in PLD-1 expression results in only a relatively small increase in 1,25(OH)2D3-stimulated total PLD activity (approximately 1.4-fold over control) at 24 h. However, significant levels of PLD-2 mRNA are detected in the keratinocytes (Fig. 1). Although PLD-2 expression is unaltered by 1,25(OH)2D3, PLD-2 is likely to contribute to the basal PLD activity, thus masking the extent of the 1,25(OH)2D3-induced change in PLD-1 activity. In fact, when we measured Rho- and ARF-stimulatable PLD-1 activity in 1,25(OH)2D3-pretreated keratinocyte homogenates, we found an approximate 3-fold increase in PLD-1 activity (Fig. 3B), consistent with our observed ~3-fold increase in PLD-1 message. Thus, the observed increase in PLD-1 mRNA is translated into elevated PLD-1 activity.

To establish a potential participation of 1,25(OH)2D3-induced PLD-1 expression/activation in the various stages of keratinocyte differentiation, we examined the time course of changes in markers of each of three stages of keratinocyte differentiation. If PLD-1 activity is to be involved in a particular stage of keratinocyte differentiation, PLD-1 expression/activation should precede changes in the appropriate marker. DNA synthesis is arrested in cells undergoing the basal to spinous transition. A significant growth arrest of proliferating keratinocytes is first induced by 1,25(OH)2D3 within approximately 8 h of exposure (Fig. 5). The expression of PLD-1 is first elevated at 8 h also. Since alterations in 1,25(OH)2D3-induced PLD-1 expression are coincident with growth arrest rather than preceding it, our result argues against a role for PLD-1 in the basal to spinous transition. We should note that our observation of a requirement for an 8-h exposure to 1,25(OH)2D3 conflicts with a previous report in mouse keratinocytes in which 1,25(OH)2D3 inhibited [3H]thymidine incorporation into DNA within 3 h (34). These investigators used as their control DNA synthesis at time 0. However, we have found changes in [3H]thymidine incorporation in vehicle-exposed keratinocytes over time and therefore have used [3H]thymidine incorporation in cells incubated with vehicle for the same period of time as the 1,25(OH)2D3-treated cells as the corresponding control value.

The expression of the cytokeratin K1 is known to mark early (spinous) keratinocyte differentiation. However, in our studies 1,25(OH)2D3 decreased K1 expression (Fig. 5); thus, our results argue against a role for PLD-1 in mediating early (spinous) differentiation, because K1 expression was not increased. However, these findings may not accurately reflect the true involvement of PLD-1 in mediating the events of early differentiation, because the results of others indicate that cytokeratin K1 expression may be decreased directly by 1,25(OH)2D3, and therefore, any effect of PLD-1 on K1 expression may be masked. Specifically, Su et al. (35) demonstrated K1 message destabilization by 1,25(OH)2D3. In addition, there exists a 1,25(OH)2D3 inhibitory element in the 3'-untranslated region of the K1 gene (7). Further experiments using lower concentrations of 1,25(OH)2D3 and longer exposures may reveal a correlation of PLD-1 expression with early keratinocyte differentiation.

Exposure to 1,25(OH)2D3 also increased transglutaminase activity, a marker of late (granular) differentiation, with maximal stimulation observed at 24 h (Fig. 6). Our result is consistent with a previous report (35), in which the authors described a peak increase of approximately 2-fold after a 24-h 1,25(OH)2D3 treatment and a slight decline by 48 h (35). These data suggest that the mouse keratinocyte behaves similarly to the human and that transglutaminase activity can serve as a marker of differentiation in our primary mouse keratinocyte system. Our time course is also consistent with a potential role for PLD activity in regulating differentiation in that PLD-1 is expressed in response to 1,25(OH)2D3 prior to the measured increase in transglutaminase activity. Additional evidence for a role for PLD-1 in differentiation is provided by our in situ hybridization study (Fig. 7). The finding that little or no expression of PLD-1 is detected in basal keratinocytes argues against its involvement in growth arrest. Instead, expression is detected strongly in the upper layers (the spinous and granular layers), consistent with PLD-1 mediating keratinocyte differentiation.

There are numerous published data supporting a role for PKC in regulating keratinocyte growth and differentiation (reviewed in Refs. 1 and 9). However, the exact role of PKC is controversial, since agents that stimulate proliferation and those that induce differentiation have each been reported to increase phosphoinositide turnover and DAG levels (36-38) and/or activate PKC (13, 39-42). The explanation for these conflicting results may reside in the fact that PKC is a family of isoenzymes (reviewed in Ref. 11), with different PKC isoenzymes involved in proliferative versus differentiative events. Thus, two agents that both stimulate PKC yet produce two different results may be activating two different PKC isoenzymes. In additional studies, treatment of keratinocytes with phorbol esters yielded paradoxical results of initial differentiation induction and subsequent growth promotion (43). These results are probably due to the ability of phorbol esters to activate multiple isoforms of PKC.

Because it is derived from phosphatidylcholine rather than from phosphoinositides, the DAG species generated by PLD (and PA phosphohydrolase) is composed of different acyl groups than DAG generated by other phospholipid-hydrolyzing enzymes. Thus, DAG generated by PLD may activate distinct PKC isoforms (reviewed in Ref. 10), leading to the expression of specific markers of keratinocyte differentiation. Numerous studies in other systems have suggested that individual PKC isoenzymes regulate specific cellular processes (reviewed in Ref. 11). For example, in a transfected rat keratinocyte cell line, PKC-eta has been shown to increase the transcription of transglutaminase, a marker of late keratinocyte differentiation, more effectively than other PKC isoforms (44). Thus, individual PKC isozymes, activated by distinct DAG species, may be responsible for determining the patterned expression of genes during keratinocyte differentiation. Alternatively, DAG derived from PLD activity may be differentially metabolized (45, 46), and/or the PA produced directly by PLD activity may itself serve a second messenger function (reviewed in Ref. 10).

Our present results are indicative of a role for 1,25(OH)2D3-induced PLD-1 expression/activity in mediating keratinocyte differentiation. Specifically, our time course studies, as well as our in situ hybridization data, support an involvement of PLD-1 in the spinous to granular transition in keratinocytes. Current experiments in our laboratory are directed toward attempting to prove this hypothesis through other methods of regulating PLD-1 expression and/or activity. Finally, our report is the first to document a 1,25(OH)2D3-elicited increase in the expression of the important phospholipid-metabolizing enzyme PLD.

    ACKNOWLEDGEMENTS

We thank Dr. Maurice Pechet for the generous gift of 1,25(OH)2D3 and Dr. Stuart Yuspa for providing the keratin 1 probe. We gratefully acknowledge Dr. Nancy Pryer for the kind provision of Rho-, ARF-, and PLD-overexpressing Sf9 cell membranes. In addition, we thank Sagarika Ray for expert technical assistance. We also express our appreciation to Dr. Michael Frohman for encouragement and many helpful discussions.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant AR45212.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

These data were presented in part at the Society for Investigative Dermatology meeting in Washington, D. C., April 1997.

Dagger To whom correspondence should be addressed: Dept. of Medicine and Cellular Biology and Anatomy, Inst. of Molecular Medicine and Genetics, Medical College of Georgia, 1120 15th St., Augusta, GA 30912.

    ABBREVIATIONS

The abbreviations used are: 1, 25(OH)2D3, 1alpha ,25-dihydroxyvitamin D3; DAG, sn-1,2-diacylglycerol; PA, phosphatidic acid; PKC, protein kinase C; PLD, phospholipase D; ARF, ADP-ribosylation factor; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate; K1, cytokeratin K1; GQ1b, II3(NeuAc)2, IV3(NeuAc)2-GgOseCer.

2 E. M. Jung, S. Betancourt-Calle, R. D. Griner, R. Mann-Blakeney, and W. B. Bollag, Carcinogenesis, in press.

    REFERENCES
Top
Abstract
Introduction
References

  1. Bikle, D. D., and Pillai, S. (1993) Endocr. Rev. 14, 3-19[Medline] [Order article via Infotrieve]
  2. Yuspa, S. H., Hennings, H., Tucker, R. W., Kilkenny, A., Lee, E., Kruszewski, F., and Roop, D. R. (1990) Papillomaviruses, pp. 211-222, Wiley-Liss, Inc., New York
  3. Berth-Jones, J., and Hutchinson, P. E. (1992) Br. J. Dermatol. 127, 71-78[Medline] [Order article via Infotrieve]
  4. Bollag, W. B., Ducote, J., and Harmon, C. S. (1995) J. Cell. Physiol. 163, 248-256[Medline] [Order article via Infotrieve]
  5. Bikle, D. D. (1995) J. Nutr. 125, 1709S-1714S[Medline] [Order article via Infotrieve]
  6. Blumenberg, M., Connolly, D. M., and Freedberg, I. M. (1992) J. Invest. Dermatol. 98, 42S-49S[Abstract]
  7. Lu, B., Rothnagel, J. A., Longley, M. A., Tsai, S. Y., and Roop, D. R. (1994) J. Biol. Chem. 269, 7443-7449[Abstract/Free Full Text]
  8. Pillai, S., Bikle, D. D., Su, M.-J., Ratnam, A., and Abe, J. (1995) J. Clin. Invest. 96, 602-609[Medline] [Order article via Infotrieve]
  9. Inohara, S. (1992) Exp. Dermatol. 1, 207-220[Medline] [Order article via Infotrieve]
  10. Exton, J. H. (1994) Biochim. Biophys. Acta 1212, 26-42[Medline] [Order article via Infotrieve]
  11. Nishizuka, Y. (1995) FASEB J. 9, 484-496[Abstract/Free Full Text]
  12. Seishima, M., Aoyama, Y., Mori, S., and Nozawa, Y. (1995) J. Invest. Dermatol. 104, 835-838[Abstract]
  13. Yada, Y., Okano, Y., and Nozawa, Y. (1991) Biochem. J. 279, 665-670[Medline] [Order article via Infotrieve]
  14. Jung, E. M., Griner, R. D., Mann-Blakeney, R., and Bollag, W. B. (1998) J. Invest. Dermatol. 110, 318-323[Abstract]
  15. Sugai, M., Hashimoto, K., Kikuchi, A., Inoue, S., Okumura, H., Matsumoto, K., Goto, Y., Moriishi, K., Syuto, B., Yoshikawa, K., Suginaka, H., and Takai, Y. (1992) J. Biol. Chem. 267, 2600-2604[Abstract/Free Full Text]
  16. Frohman, M. A., and Morris, A. J. (1996) Curr. Biol. 6, 945-947[Medline] [Order article via Infotrieve]
  17. Kuribara, H., Tago, K., Yokozeki, T., Sasaki, T., Takai, Y., Morii, N., Narumiya, S., Katada, T., and Kanaho, Y. (1995) J. Biol. Chem. 270, 25667-25671[Abstract/Free Full Text]
  18. Kodaki, T., and Yamashita, S. (1997) J. Biol. Chem. 272, 11408-11413[Abstract/Free Full Text]
  19. Hammond, S. M., Altshuller, Y. M., Sung, T.-C., Rudge, S. A., Rose, K., Engebrecht, J., Morris, A. J., and Frohman, M. A. (1995) J. Biol. Chem. 270, 29640-29643[Abstract/Free Full Text]
  20. Colley, W. C., Altshuller, Y. M., Sue-Ling, C. K., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Bollag, R. J., Bollag, W. B., and Frohman, M. A. (1997) Biochem. J. 326, 745-753[Medline] [Order article via Infotrieve]
  21. Park, S.-K., Provost, J. J., Bae, C. D., Ho, W.-T., and Exton, J. H. (1997) J. Biol. Chem. 272, 29263-29271[Abstract/Free Full Text]
  22. Colley, W., Sung, T.-C., Roll, R., Jenco, J., Hammond, S. M., Altshuller, Y. M., Bar-Sagi, D., Morris, A. J., and Frohman, M. A. (1997) Curr. Biol. 7, 191-201[Medline] [Order article via Infotrieve]
  23. Yoshimura, S., Nakashima, S., Ohguchi, K., Sakai, H., Shinoda, J., Sakai, N., and Nozawa, Y. (1996) Biochem. Biophys. Res. Commun. 225, 494-499[CrossRef][Medline] [Order article via Infotrieve]
  24. Ohguchi, K., Nakashima, S., Tan, Z., Banno, Y., Dohi, S., and Nozawa, Y. (1997) J. Biol. Chem. 272, 1990-1996[Abstract/Free Full Text]
  25. Yuspa, S. H., and Harris, C. C. (1974) Exp. Cell Res. 86, 95-105[Medline] [Order article via Infotrieve]
  26. Bollag, W. B. (1998) Methods Mol. Biol. 105, 151-160[Medline] [Order article via Infotrieve]
  27. Iwasaki-Bessho, Y., Banno, Y., Yoshimura, S., Ito, Y., Kitajima, Y., and Nozawa, Y. (1998) J. Invest. Dermatol. 110, 376-382[Abstract]
  28. Folk, J. E., and Chung, S. I. (1985) Methods Enzymol. 113, 358-375[Medline] [Order article via Infotrieve]
  29. Wilkinson, D. G. (1992) In Situ Hybridization: A Practical Approach, pp. 75-84, IRL Press, Oxford
  30. Geilen, C. C., Bektas, M., Wieder, T., Kodelja, V., Goerdt, S., and Orfanos, C. E. (1997) J. Biol. Chem. 272, 8997-9001[Abstract/Free Full Text]
  31. Kim, H.-J., Abdelkader, N., Katz, M., and McLane, J. A. (1992) J. Cell. Physiol. 151, 579-587[Medline] [Order article via Infotrieve]
  32. Matkovits, T., and Christakos, S. (1995) Endocrinology 136, 3971-3982[Abstract]
  33. Chang, P.-L., Ridall, A. L., and Prince, C. W. (1994) Endocrinology 135, 863-869[Abstract]
  34. Matsumoto, K., Hashimoto, K., Nishida, Y., Hashiro, M., and Yoshikawa, K. (1990) Biochem. Biophys. Res. Commun. 166, 916-923[Medline] [Order article via Infotrieve]
  35. Su, M.-J., Bikle, D. D., Mancianti, M.-L., and Pillai, S. (1994) J. Biol. Chem. 269, 14723-14729[Abstract/Free Full Text]
  36. Johnson, R. M., King, K. L., and Morhenn, V. B. (1992) Second Messengers Phosphoproteins 14, 21-37[Medline] [Order article via Infotrieve]
  37. Talwar, H. S., Fisher, G. J., and Voorhees, J. J. (1990) J. Invest. Dermatol. 95, 705-710[Abstract]
  38. Pillai, S., and Bikle, D. D. (1992) J. Clin. Invest. 90, 42-51[Medline] [Order article via Infotrieve]
  39. Denning, M. F., Dlugosz, A. A., Williams, E. K., Szallasi, Z., Blumberg, P. M., and Yuspa, S. H. (1995) Cell Growth Differ. 6, 149-157[Abstract]
  40. Hanafin, N. M., Persons, K. S., and Holick, M. F. (1995) J. Cell. Biochem. 57, 362-370[Medline] [Order article via Infotrieve]
  41. Jaken, S., and Yuspa, S. H. (1988) Carcinogenesis 9, 1033-1038[Abstract]
  42. Yada, Y., Ozeki, T., Meguro, S., Mori, S., and Nozawa, Y. (1989) Biochem. Biophys. Res. Commun. 163, 1517-1522[Medline] [Order article via Infotrieve]
  43. Yuspa, S. H., Ben, T., Hennings, H., and Lichti, U. (1982) Cancer Res. 42, 2344-2349[Abstract]
  44. Ueda, E., Ohno, S., Kuroki, T., Livneh, E., Yamada, K., Yamanishi, K., and Yasuno, H. (1996) J. Biol. Chem. 271, 9790-9794[Abstract/Free Full Text]
  45. Bollag, W. B., Barrett, P. Q., Isales, C. M., and Rasmussen, H. (1991) Endocrinology 128, 231-241[Abstract]
  46. Florin-Christensen, J., Florin-Christensen, M., Delfino, J. M., Stegmann, T., and Rasmussen, H. (1992) J. Biol. Chem. 267, 14783-14789[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.